Novavax Inc. (NVAX), on Tuesday announced positive top-line-data from its Phase II dose-ranging clinical trial of its vaccine for respiratory syncytial virus in women of childbearing age. The company in a statement added that the progress supported progression to the next stage of advanced clinical testing.
The Phase II clinical study comprising 330 women of child-bearing age, examined the safety and immunogenicity of two-dose levels of Novavax' RSV F protein nanoparticle vaccine candidate with and without aluminum phosphate as an adjuvant.
The company said that the participants reported mild to moderate headache, fatigue and muscle ache, and added that it shall continue to evaluate safety over a total period of six months and immunogenicity for four months respectively.
Through the trial, the company believes that the antibodies in such vaccinated women could be expected to be naturally transferred to their infants in utero and thereby conferring passive protection at the earliest stage of life, as infants are extremely vulnerable to severe respiratory disease due to RSV.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.